AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04159714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix contact lens
Description: Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
Study NCT00576511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 4 mg o.d.
Study NCT00576511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo o.d.
Study NCT01776957 — intervention group
Intervention type: DEVICE
Intervention: Device: Intrauterine device (IUD)
Description: Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
Study NCT03460041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: caudal magnesium sulphate added to bupivacaine for pain management
Study NCT03460041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetedomedine
Description: Caudal dexmetedomedine added to bupivacaine for pain management
Study NCT03460041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Caudal bupivacaine for pain management
Study NCT04023201 — intervention group
Intervention type: OTHER
Intervention: Nocturnal symptoms
Description: Parkinson's disease patients with or without nocturnal symptoms
Study NCT02427009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position for 1 hour after blood patch
Description: After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
Study NCT02427009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood patch
Description: And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
Study NCT01640977 — intervention group
Intervention type: PROCEDURE
Intervention: Open PLIF (posterior lumbar interbody fusion)
Description: The PLIF procedure achieves access to the degenerated disc from the back of the spine.
Study NCT01640977 — intervention group
Intervention type: PROCEDURE
Intervention: MAS PLIF
Description: The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
Study NCT01493713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the correlation of overall different objective response.
Description: Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
Study NCT00003819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study NCT00003819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TF(c)-KLH conjugate vaccine
Study NCT00003819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thomsen-Friedenreich antigen
Study NCT00003819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Study NCT02597608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLP: Livelihoods
Description: Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
Study NCT02597608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLP: Nutrition
Description: Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
Study NCT02597608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shiree: Livelihoods
Description: Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
Study NCT02597608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shiree: Nutrition
Description: Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
Study NCT02597608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPPR: Livelihoods
Description: Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
Study NCT02597608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UPPR: Nutrition
Description: Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
Study NCT02597608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UPPR: Control
Description: No interventions provided.
Study NCT02055586 — intervention group
Intervention type: OTHER
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT-PET/MRI
Study NCT02055586 — intervention group
Intervention type: DEVICE
Intervention: positron emission tomography
Description: Undergo FLT-PET/MRI
Study NCT02055586 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: Undergo FLT-PET/MRI
Study NCT05461040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optic capture
Description: optic capture of Intraocular lens without anterior vitrectomy
Study NCT05461040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-the-bag implantation of Intraocular lens
Description: in-the-bag implantation of Intraocular lens with anterior vitrectomy
Study NCT04585919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired Screening Intervention
Description: The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
Study NCT02551458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic surgery
Study NCT02551458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveillance and rescue surgery in cases of resectable loco-regional recurrence
Study NCT03879070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle active and passive mobilization using an Ankle mobilization device
Description: The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
Study NCT02432599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F18-choline PET examination
Description: F18-choline PET examination will be performed before surgery
Study NCT02465450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101 (lenabasum)
Description: Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
Study NCT02465450 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
Study NCT00411320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid-dexamethasone
Description: 2 week steroid trial
Study NCT00650962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary resuscitation
Description: 10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
Study NCT00650962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm analysis
Description: Rhythm analysis as soon as AED is ready
Study NCT02739126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial EBUS biopsy
Description: Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
Study NCT02739126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Types of Radial Ultrasound probes
Description: The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
Study NCT02830139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
Study NCT02830139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical colorectal resection
Description: radical colorectal resection with lymphadenectomy
Study NCT02830139 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical colorectal resection
Description: radical colorectal resection with lymphadenectomy
Study NCT02830139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin , Capecitabine
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study NCT02830139 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxaliplatin , Capecitabine
Description: XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study NCT02830139 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline , Cisplatin , 5-Fu
Study NCT02005796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study NCT01253161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide Long Acting Release (LAR)
Description: Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Study NCT03945630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior Quadratus Lumborum Block
Description: Interfascial plane block
Study NCT03945630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No QLB
Study NCT04201340 — intervention group
Intervention type: DEVICE
Intervention: DRI OCT Triton with SS-OCT Angio software
Description: The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
Study NCT04201340 — intervention group
Intervention type: DEVICE
Intervention: Cirrus HD-OCT 5000
Description: The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
Study NCT04201340 — intervention group
Intervention type: DEVICE
Intervention: TRC-50DX
Description: The TRC-50DX retinal camera images the fundus used for diagnostic purposes
Study NCT02430051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment
Description: The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
Study NCT04174898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human Mesenchymal Stem Cell (MSC) infusion therapy
Description: Subjects will be infused with 100million human MSCs
Study NCT03419832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAT Form
Description: The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
Study NCT03419832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Form
Description: The regular IRB approved version.
Study NCT02217501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study NCT02217501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study NCT02217501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study NCT02217501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study NCT00675675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
Study NCT00675675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minimal Contact Waitlist
Description: Bimonthly phone check-in to assess clinical status and enhance subject retention
Study NCT02851225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine transmission of biological results
Description: telemedicine transmission of biological informations
Study NCT02506517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT04289012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Helicobacter Pylori screening by UBT
Description: The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
Study NCT01100827 — intervention group
Intervention type: OTHER
Intervention: EGFR mutation status in patients
Study NCT02007915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate Disodium
Description: Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
Study NCT02745574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined maneuver
Description: Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
Study NCT02745574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion
Description: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
Study NCT01239459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition
Study NCT01239459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55
Study NCT02297139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT01924533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
Study NCT01924533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
Study NCT01924533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
Study NCT01924533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Study NCT03738930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI based mHealth system
Description: AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
Study NCT04061785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Judo4Balance - 12 week judo inspired exercise program
Description: 12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
Study NCT03072186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near-infrared light nasal endoscope used with ICG
Description: Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
Study NCT02750995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NPMW-peptide vaccine
Description: Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
Study NCT02750995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
Study NCT02889419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of underwear Selfia®
Description: Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
Study NCT00323063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00323063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00323063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT05512117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline insertion
Description: Midline catheter insertion